TY - JOUR
T1 - Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens
AU - Goto, Naoe
AU - Tsurumi, Hisashi
AU - Goto, Hideko
AU - Shimomura, Yoriko Ino
AU - Kasahara, Senji
AU - Hara, Takeshi
AU - Yasuda, Ichiro
AU - Shimizu, Masahito
AU - Murakami, Nobuo
AU - Yoshikawa, Takeshi
AU - Fukuno, Kenji
AU - Takahashi, Takeshi
AU - Kito, Yusuke
AU - Takami, Tsuyoshi
AU - Moriwaki, Hisataka
PY - 2012/5
Y1 - 2012/5
N2 - Serum concentration of soluble interleukin-2 receptor (sIL-2R) predicts the clinical outcome of patients with aggressive non-Hodgkin's lymphoma treated with the cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen without rituximab. In the present study, we aim to re-assess the prognostic significance of serum sIL-2R for diffuse large B cell lymphoma (DLBCL) patients treated with CHOP plus rituximab and to assess sIL-2R with subtype of DLBCL, such as GCB type and non- GCB type. Two hundred and thirty-three patients with DLBCL were enrolled between December 2002 and March 2008. To evaluate serum levels of sIL-2R, venous blood samples were drawn from patients immediately before initiation of treatment. Serum sIL-2R was determined by sandwich enzyme-linked immunosorbent assay. The 5-year overall survival (OS) rates for patients with sIL-2R levels of ≥2,000 (110 cases) and <2,000 U/mL (123 cases) were 54.2% and 89.0% (P<0.0001), respectively. Multivariate analysis using the proportional-hazards model revealed that serum sIL-2R (P=0.0099) and extranodal involvement sites (P=0.0392) were independent prognostic factors for OS and that clinical stage (P=0.0168), performance status (P= 0.0181), sIL-2R (P=0.0232), and LDH (P=0.0316) were independent prognostic factors for progression-free survival in sIL-2R and every factor of the International Prognostic Index. Serum sIL-2R might be a useful prognostic factor for DLBCL patients in the rituximab era.
AB - Serum concentration of soluble interleukin-2 receptor (sIL-2R) predicts the clinical outcome of patients with aggressive non-Hodgkin's lymphoma treated with the cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen without rituximab. In the present study, we aim to re-assess the prognostic significance of serum sIL-2R for diffuse large B cell lymphoma (DLBCL) patients treated with CHOP plus rituximab and to assess sIL-2R with subtype of DLBCL, such as GCB type and non- GCB type. Two hundred and thirty-three patients with DLBCL were enrolled between December 2002 and March 2008. To evaluate serum levels of sIL-2R, venous blood samples were drawn from patients immediately before initiation of treatment. Serum sIL-2R was determined by sandwich enzyme-linked immunosorbent assay. The 5-year overall survival (OS) rates for patients with sIL-2R levels of ≥2,000 (110 cases) and <2,000 U/mL (123 cases) were 54.2% and 89.0% (P<0.0001), respectively. Multivariate analysis using the proportional-hazards model revealed that serum sIL-2R (P=0.0099) and extranodal involvement sites (P=0.0392) were independent prognostic factors for OS and that clinical stage (P=0.0168), performance status (P= 0.0181), sIL-2R (P=0.0232), and LDH (P=0.0316) were independent prognostic factors for progression-free survival in sIL-2R and every factor of the International Prognostic Index. Serum sIL-2R might be a useful prognostic factor for DLBCL patients in the rituximab era.
KW - DLBCL
KW - R-CHOP
KW - Soluble interleukin-2 receptor (sIL-2R)
UR - https://www.scopus.com/pages/publications/84861441408
UR - https://www.scopus.com/pages/publications/84861441408#tab=citedBy
U2 - 10.1007/s00277-011-1363-4
DO - 10.1007/s00277-011-1363-4
M3 - Article
C2 - 22183251
AN - SCOPUS:84861441408
SN - 0939-5555
VL - 91
SP - 705
EP - 714
JO - Annals of Hematology
JF - Annals of Hematology
IS - 5
ER -